Background: Subclinical cardiac dysfunction is a growing concern in cancer patients receiving chemotherapy. Early detection before treatment initiation is crucial to prevent overt cardiotoxicity. Objective: This study evaluates the association between comorbidity burden and subclinical cardiac dysfunction, using echocardiographic parameters, in cancer patients prior to chemotherapy. Method: This retrospective observational study analysed 110 cancer patients who underwent transthoracic echocardiography before chemotherapy. Comorbidity burden was assessed using the Charlson Comorbidity Index (CCI) and Karnofsky Performance Status (KPS). Echocardiographic evaluation included Global Longitudinal Strain (GLS), the E/e[ ] ratio (early transmitral inflow velocity to early diastolic mitral annular velocity) and left atrial volume index (LAVI). Subclinical dysfunction was defined as [ ] and/or diastolic dysfunction. Spearman’s rank correlation and multivariable linear regression were performed. Results: Abnormal GLS ([ ]) was found in 68 patients (61.8%), while 42 patients (38.2%) had normal GLS values. Higher comorbidity burden (CCI) was modestly associated with worse GLS ([ ], [ ]) and higher E/e[ ] ([ ], [ ]), whereas better functional status (Karnofsky score) correlated with more preserved GLS ([ ], [ ]). Higher age was independently associated with higher E/e[ ] ([ ], 95% CI 0.005–0.065, [ ], [ ]), whereas the association between CCI and E/e[ ] was of borderline significance ([ ], 95% CI −0.024–0.396, [ ], [ ]). Conclusion: This study showed a significant correlation between comorbidity indices and GLS as well as diastolic function parameters. This suggests that comorbidity burden and functional status are significantly associated with subclinical cardiac abnormalities before chemotherapy.
Background: Postoperative pain remains common after surgery, and opioid-related adverse effects motivate multimodal alternatives. The serratus plane block (SPB) is used for breast surgery, but its comparative benefit remains uncertain. Methods: We searched PubMed, the Cochrane Library, and ProQuest for English-language randomized trials and cohort studies published between January 2019 ...
10 January 2026 in JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga
Highlights: Epirubicin (anthracycline-based) showed the highest cost-effectiveness. Taxane-based regimens were less cost-effective compared with anthracyclines. Abstract Introduction: Breast cancer, particularly stage 4, contributes significantly to global morbidity and mortality. Anthracycline- and taxane-based chemotherapies are commonly used for metastatic breast cancer, but their high costs necessitate a cost-effectiveness analysis to inform healthcare financing. This study aimed to assess the cost-effectiveness of these therapies for patients with stage 4 breast cancer at Dr. Soetomo General Hospital, Surabaya. Methods: A retrospective review of medical records from 124 stage 4 breast cancer patients treated in inpatient and outpatient settings was conducted. Effectiveness rates and cost data for epirubicin, doxorubicin, docetaxel, and paclitaxel were analyzed. Data processing involved basic calculations in Google Sheets, and the average cost-effectiveness ratio (ACER) and incremental cost-effectiveness ratio (ICER) were calculated. Ethical clearance was obtained. Results: Epirubicin was the most cost-effective, with an ACER of 958,878 Indonesian Rupiah (IDR) and an ICER of -IDR 2,603,667. Conclusion: Epirubicin is the most cost-effective chemotherapy option for stage 4 breast cancer, supporting its use in resource-limited settings and guiding cancer therapy decisions.